CN1276764C - 一种中药组合物在制备治疗缺铁性贫血药物中的应用 - Google Patents
一种中药组合物在制备治疗缺铁性贫血药物中的应用 Download PDFInfo
- Publication number
- CN1276764C CN1276764C CN 03124713 CN03124713A CN1276764C CN 1276764 C CN1276764 C CN 1276764C CN 03124713 CN03124713 CN 03124713 CN 03124713 A CN03124713 A CN 03124713A CN 1276764 C CN1276764 C CN 1276764C
- Authority
- CN
- China
- Prior art keywords
- radix
- weight
- granule
- group
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000008187 granular material Substances 0.000 title abstract description 26
- 239000008280 blood Substances 0.000 title abstract description 22
- 210000004369 blood Anatomy 0.000 title abstract description 18
- 238000000034 method Methods 0.000 title abstract description 6
- 241000411851 herbal medicine Species 0.000 title description 2
- 238000011282 treatment Methods 0.000 claims abstract description 34
- 238000000605 extraction Methods 0.000 claims abstract description 9
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 238000010992 reflux Methods 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 13
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 10
- 239000009636 Huang Qi Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 abstract description 15
- 239000000463 material Substances 0.000 abstract description 2
- 238000010438 heat treatment Methods 0.000 abstract 2
- 241000118825 Alkanna tinctoria Species 0.000 abstract 1
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 241000510667 Conioselinum Species 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 230000002907 effect on anemia Effects 0.000 abstract 1
- 238000011127 radiochemotherapy Methods 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 21
- 201000010099 disease Diseases 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 241000700199 Cavia porcellus Species 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 208000024891 symptom Diseases 0.000 description 14
- 210000003743 erythrocyte Anatomy 0.000 description 11
- 208000007502 anemia Diseases 0.000 description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 229960004397 cyclophosphamide Drugs 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- 210000001185 bone marrow Anatomy 0.000 description 5
- 208000002173 dizziness Diseases 0.000 description 5
- 206010047513 Vision blurred Diseases 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 206010022971 Iron Deficiencies Diseases 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 206010037549 Purpura Diseases 0.000 description 2
- 241001672981 Purpura Species 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 210000004976 peripheral blood cell Anatomy 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- NEZONWMXZKDMKF-JTQLQIEISA-N Alkannin Chemical compound C1=CC(O)=C2C(=O)C([C@@H](O)CC=C(C)C)=CC(=O)C2=C1O NEZONWMXZKDMKF-JTQLQIEISA-N 0.000 description 1
- 201000002045 Ancylostomiasis Diseases 0.000 description 1
- 208000033211 Ankylostomiasis Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 208000005232 Glossitis Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 108010017480 Hemosiderin Proteins 0.000 description 1
- 206010020376 Hookworm infection Diseases 0.000 description 1
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 1
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 1
- BVRYLTBIGIAADD-MRXNPFEDSA-N Isobutylshikonin Chemical compound C1=CC(O)=C2C(=O)C([C@@H](CC=C(C)C)OC(=O)C(C)C)=CC(=O)C2=C1O BVRYLTBIGIAADD-MRXNPFEDSA-N 0.000 description 1
- 241001071917 Lithospermum Species 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 206010027540 Microcytosis Diseases 0.000 description 1
- 229930192627 Naphthoquinone Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 241001482237 Pica Species 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000005485 Thrombocytosis Diseases 0.000 description 1
- 208000022440 X-linked sideroblastic anemia 1 Diseases 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- WNFXUXZJJKTDOZ-HNNXBMFYSA-N [(1s)-1-(5,8-dihydroxy-1,4-dioxonaphthalen-2-yl)-4-methylpent-3-enyl] acetate Chemical compound C1=CC(O)=C2C(=O)C([C@@H](OC(C)=O)CC=C(C)C)=CC(=O)C2=C1O WNFXUXZJJKTDOZ-HNNXBMFYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- UNNKKUDWEASWDN-UHFFFAOYSA-N alkannin Natural products CC(=CCC(O)c1cc(O)c2C(=O)C=CC(=O)c2c1O)C UNNKKUDWEASWDN-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000011902 gastrointestinal surgery Methods 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000008941 guipiwan Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 201000004108 hypersplenism Diseases 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- BVRYLTBIGIAADD-UHFFFAOYSA-N isobutyryl shikonin Natural products C1=CC(O)=C2C(=O)C(C(CC=C(C)C)OC(=O)C(C)C)=CC(=O)C2=C1O BVRYLTBIGIAADD-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- -1 naphthoquinone compound Chemical class 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- WNFXUXZJJKTDOZ-UHFFFAOYSA-N shikonin acetate Natural products C1=CC(O)=C2C(=O)C(C(OC(C)=O)CC=C(C)C)=CC(=O)C2=C1O WNFXUXZJJKTDOZ-UHFFFAOYSA-N 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N tenuazonic acid Chemical compound CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
组别 | 剂量(g/kg) | WBC(×109个/L) | RBC(×1012个/L) | Hb(g/L) | Pt 骨(×109个/L) | 髓有核细胞数(×101个/股骨) |
正常对照组 | 等体积水 | 9.6±2.1 | 5.6±0.4 | 124.1±5.4 | 194.9±34.2 | 1012±384 |
CY模型组 | 等体积水 | 2.9±0.4△ | 6.4±0.3* | 118.0±3.8* | 97.2±9.3△ | 315±186△ |
CY+四物汤 | 10.0 | 6.1±1.1*** | 6.6±0.4* | 121.4±6.8* | 129.8±12.3*** | 767±272** |
CY+本发明颗粒 | 8.6 | 4.2±0.8*** | 6.7±0.3* | 119.3±6.4* | 139.5±14.5*** | 486±178* |
CY+本发明颗粒 | 17.2 | 5.2±1.1*** | 6.7±0.4* | 120.8±5.6* | 163.3±16.3*** | 734±209** |
CY+本发明颗粒 | 34.4 | 6.0±1.2*** | 6.9±0.2 | 123.1±4.5* | 172.0±22.5*** | 845±266** |
组别 | 剂量(g/kg) | 脾指数(g/100g) |
正常对照组 | 等体积水 | 0.487±0.167 |
CY模型组 | 等体积水 | 0.221±0.082△ |
CY+本发明颗粒 | 10.0 | 0.448±0.071*** |
CY+本发明颗粒 | 8.6 | 0.391±0.120** |
CY+本发明颗粒 | 17.2 | 0.427±0.082*** |
CY+本发明颗粒 | 34.4 | 0.455±0.057*** |
组别 | 剂量(g/kg) | 体重(g) | WBC(×109个/L) | RBC(×1012个/L) | Hb(g/L) | Pt(×109个/L) |
正常照组 | 等体积水 | 25.2+5.3 | 9.1+1.0 | 6.4±0.5 | 116.9±6.2 | 229.1±32.1 |
CO60模型组 | 等体积水 | 22.1±2.7△ | 5.1±0.5△ | 6.8±0.3 | 106.9±6.0△ | 183.4±16.1△ |
CO60+四物汤 | 10.0 | 25.2±1.6** | 6.3±0.4*** | 6.9±0.3 | 127.7±8.8*** | 205.8±26.4** |
CO60+本发明颗粒 | 17.22 | 5.8±2.3** | 7.2±0.6*** | 7.0±0.4 | 136.0±5.1*** | 209.3±18.1** |
CO60+本发明颗粒 | 34.4 | 26.7±2.5** | 7.4±0.6*** | 7.2±0.2 | 135.8±8.4*** | 225.2±24.8*** |
组别 | 例数 | 男/女 | 年龄(岁) | 症状积分(分) |
试验组 | 71 | 22/49 | 43.00±12.99 | 10.72±4.23 |
对照组 | 30 | 9/21 | 40.10±10.95 | 10.63±2.48 |
组别 | 例数 | 临床控制(%) | 显效(%) | 显效以上(%) | 有效(%) | 无效(%) | 总有效(%) |
试验组 | 71 | 2(2.8) | 19(26.76) | 21(29.58) | 40(56.34) | 10(14.08) | 61(85.92) |
对照组 | 30 | 2(6.67) | 2(6.67) | 16(53.33) | 10(33.33) | 20(66.67) |
组别 | 例数 | 治疗前症状总积分(分) | 治疗后症状总积分(分) |
试验组 | 71 | 10.72±4.32 | 5.11±3.28 |
对照组 | 30 | 10.63±2.48 | 6.70±2.88 |
试验组 | 对照组 | |||||||
治疗前 | 治疗后 | 治疗前 | 治疗后 | |||||
例 | X±SD | 例 | X±SD | 例 | X±SD | 例 | X±SD | |
头晕眼花 | 60 | 1.99±0.61 | 22/69 | 0.80±0.63 | 29 | 2.14±0.52 | 3.29 | 1.21±0.62 |
神疲乏力 | 69 | 2.00±0.62 | 16/69 | 0.91±0.61 | 29 | 1.93±0.37 | 4/29 | 1.21±0.62 |
少气懒言 | 53 | 1.83±0.64 | 20/53 | 0.76±0.67 | 22 | 1.68±0.48 | 4/22 | 1.09±0.68 |
纳少 | 44 | 1.52±0.70 | 19/44 | 0.67±0.64 | 20 | 1.30±0.47 | 7/20 | 0.67±0.66 |
失眠 | 40 | 1.53±0.78 | 10/40 | 0.79±0.61 | 23 | 1.43±0.51 | 9/23 | 0.78±0.74 |
心悸 | 38 | 1.61±0.75 | 17/38 | 0.71±0.69 | 18 | 1.43±0.62 | 4/18 | 0.83±0.51 |
自汗 | 11 | 1.55±0.52 | 5/11 | 0.50±0.67 | 8 | 1.13±0.35 | 4/8 | 0.63±0.74 |
面色苍白 | 45 | 1.60±0.65 | 14/45 | 0.84±0.71 | 16 | 1.50±0.63 | 4/16 | 1.12±0.60 |
手足麻木 | 28 | 1.57±0.50 | 9/28 | 0.69±0.54 | 10 | 1.60±0.52 | 2/10 | 1.13±0.58 |
月经不调 | 28 | 1.82±0.72 | 6/28 | 1.14±0.85 | 11 | 1.64±0.50 | 3/11 | 0.81±0.60 |
试验组 | 对照组 | |||||||
例 | 治疗前 | 例 | 治疗后 | 例 | 治疗前 | 例 | 治疗后 | |
HB | 70 | 90.30±11.94 | 70 | 105.3±12.8 | 30 | 88.93±11.68 | 30 | 99.28±14.57 |
RBC | 36 | 3.266±0.41 | 36 | 3.68±0.46 | 15 | 3.27±0.66 | 15 | 4.51±0.47 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03124713 CN1276764C (zh) | 2003-07-30 | 2003-07-30 | 一种中药组合物在制备治疗缺铁性贫血药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03124713 CN1276764C (zh) | 2003-07-30 | 2003-07-30 | 一种中药组合物在制备治疗缺铁性贫血药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1513500A CN1513500A (zh) | 2004-07-21 |
CN1276764C true CN1276764C (zh) | 2006-09-27 |
Family
ID=34239552
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 03124713 Expired - Lifetime CN1276764C (zh) | 2003-07-30 | 2003-07-30 | 一种中药组合物在制备治疗缺铁性贫血药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1276764C (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103381217B (zh) * | 2013-05-13 | 2015-12-09 | 深圳国源国药有限公司 | 一种六味补血胶囊及其质量控制方法与应用 |
CN104855938A (zh) * | 2015-04-29 | 2015-08-26 | 桐城市佳明农业发展有限公司 | 一种香菇鸡肉酱及其制备方法 |
CN105214003A (zh) * | 2015-11-10 | 2016-01-06 | 李玉宾 | 一种治疗贫血的药物组合物及其制备方法 |
CN106214823A (zh) * | 2016-08-10 | 2016-12-14 | 湖南敬和堂制药有限公司 | 治疗肿瘤放化疗后毒副作用的中药组合物及其制备方法 |
-
2003
- 2003-07-30 CN CN 03124713 patent/CN1276764C/zh not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1513500A (zh) | 2004-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1840128A (zh) | 一种治疗心血管疾病的药物 | |
CN1167454C (zh) | 一种通过神阙穴进行排毒的中药组合物及其制备方法 | |
CN1965966A (zh) | 用于治疗脑血管病的中药组合物及其制备方法与应用 | |
CN101037651A (zh) | 灵芝香蕈保健酒及其制作方法 | |
CN1297291C (zh) | 一种戒除毒瘾的药物及其制备方法 | |
CN100493586C (zh) | 治疗乳腺癌、肝癌或肺癌的口服液及其生产方法 | |
CN1276764C (zh) | 一种中药组合物在制备治疗缺铁性贫血药物中的应用 | |
CN1293899C (zh) | 一种用于治疗高血压的藤丹胶囊 | |
CN1233354C (zh) | 一种治疗食管癌的中药制剂 | |
CN1990033A (zh) | 一种治疗高血压、血稠、动脉硬化的药物 | |
CN1259095C (zh) | 一种安脑降压药物及其制备方法和应用 | |
CN1111054C (zh) | 一种治疗中风的药物及其生产方法 | |
CN1593493A (zh) | 辅康艾制剂及其制备方法 | |
CN104147570A (zh) | 一种治疗小儿缺铁性贫血的中药制剂 | |
CN1251741C (zh) | 防治贫血病的药物及制备方法 | |
CN1253188C (zh) | 一种治疗高血压的药物及其制备方法 | |
CN112206279B (zh) | 一种治疗室性心律失常的中药组合物及其制备方法和应用 | |
CN1183933C (zh) | 治疗肾功能不全的药物及其制备方法 | |
CN1263490C (zh) | 一种助阳药及其制备方法 | |
CN1289139C (zh) | 一种治疗结肠炎症的药物及其制备方法 | |
CN1063077C (zh) | 一种降血脂的中药药剂及其制法 | |
CN1931256A (zh) | 一种用于戒毒的中药胶囊制剂及其制备方法 | |
CN1850265A (zh) | 一种治疗肾阳虚证的中药及制备方法 | |
CN1239179C (zh) | 一种治疗糖尿病的中药及其制备方法 | |
CN1528430A (zh) | 治疗冠心病、病毒性心肌炎的中药制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Application of a traditional Chinese medicine composition in preparing medicine for treating iron deficiency anemia Effective date of registration: 20211216 Granted publication date: 20060927 Pledgee: Hunan Liuyang Rural Commercial Bank Co.,Ltd. Beisheng sub branch Pledgor: HUNAN JINGHETANG PHARMACEUTICAL Co.,Ltd. Registration number: Y2021980015281 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230111 Granted publication date: 20060927 Pledgee: Hunan Liuyang Rural Commercial Bank Co.,Ltd. Beisheng sub branch Pledgor: HUNAN JINGHETANG PHARMACEUTICAL Co.,Ltd. Registration number: Y2021980015281 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Application of a Chinese medicine composition in the preparation of drugs for the treatment of iron deficiency anemia Effective date of registration: 20230117 Granted publication date: 20060927 Pledgee: China Construction Bank Corporation Liuyang sub branch Pledgor: HUNAN JINGHETANG PHARMACEUTICAL Co.,Ltd. Registration number: Y2023430000007 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
CX01 | Expiry of patent term |
Granted publication date: 20060927 |
|
CX01 | Expiry of patent term |